title: Therapeutic oligonucleotides: the road not taken.
abstract: Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.
authors.affiliation: Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA. cstein@montefiore.org
authors.forename: Cy A
authors.initials: CA
authors.lastname: Stein
authors.forename: Sanjay
authors.initials: S
authors.lastname: Goel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D009841:Oligonucleotides / Q000008:administration & dosage*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D014157:Transcription Factors / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; C111931:ELF4 protein, human; C569652:LY 2275796; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D014157:Transcription Factors